Candida glabrata causes approximately 5 to 15% of nonalbicans Candida infections (2). Amphotericin B or high doses of fluconazole have been the "gold standard" for management of all systemic yeast infections (2, 5, 9) . Voriconazole, a new triazole antifungal drug, has lower MICs than fluconazole and itraconazole for C. glabrata (1, 4, 5) . We describe a case in which a patient with infection due to C. glabrata was successfully treated with the oral formulation of voriconazole delivered by jejunostomy tube.
